Loading...
logo
  • Home
  • Mechanism of Action
  • Efficacy Profile
    • Efficacy Profile
    • Efficacy F-VASI
    • Efficacy T-VASI
    • Ruxolitinib Cream Case Reports
  • Safety Profile
  • Dosing
  • Setting Expectations
  • Download
  • Patient Support

Efficacy PROFILE

Ruxolitinib Cream Case Reports

headerImg
Reference:
  1. 9. Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D. Two phase 3, randomized, controlled trials of Ruxolitinib cream for vitiligo. New England Journal of Medicine. 2022 Oct 20;387(16):1445-55. Supplementary available at: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2118828/suppl_file/nejmoa2118828_appendix.pdf. Last accessed: 4.12.2024.

Get in Touch With Us.

At Rxilient, we believe in empowering patients and healthcare providers with the tools and information needed to achieve the best outcomes. Explore our collection of downloadable guides, tips, and educational materials to stay informed and confident throughout your treatment journey.

Leave your contact details and we will get in touch with you as soon as we can.

TERMS of use Privacy policy
footerLogo

Rxilient Medical (Hong Kong) Limited
Unit 2106, 21st Floor, Island Place Tower, No.510 King’s Road, North Point, Hong Kong
Tel: +852 2369 3889

For healthcare professionals practising in Hong Kong only. LUM/HKG/DOC-101/ 2025/rev.01

Scan to download Lumirix® Prescribing Information

QRCode

Copyrights © 2025 All Rights Reserved

icon

Are you a healthcare professional from Hong Kong?

icon

This site is intended for healthcare professionals practising in Hong Kong only.

icon

Access Restricted

This site is intended for healthcare professionals practising in Hong Kong only.

You do not have permission to access this content.

Access denied. Please contact the site administrator for assistance.